The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition

Aug 22, 2016
1600 Pages - Pub ID: KLI15067157
Share this report
 
Online Download $4,995
Departmental Site License (one location, 10 users) $7,495
Global Site License $9,990

What is the Size of the World In Vitro Diagnostic Test Market?


The global in vitro diagnostics (IVD) market is currently 60.5 billion dollars.  The IVD market segment for IVD reagents, kits, and instruments will grow, but in a complex pattern that involves challenges to growth in traditional categories and reliable large markets combined with opportunities in novel tests and growth nations.  This is the finding of Kalorama Information’s comprehensive report, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th edition, based on a study of IVD released every 2 years that analyzes every segment of IVD testing with trend analysis, IVD market forecasts and company profiles.  The 1,600-page study is used by the IVD industry for business planning efforts.

 In Vitro Diagnostic Growth Factors Include:

  • Aging Population 
  • Disease Incidence, Notably Cancer and Infectious Disease 
  • New Biomarkers 
  • Increased Insurance and Spending in Emerging Nations 
There are challenges to the IVD industry's growth. IVD manufacturers' development of IVD product choices have been a boon for medical care, it also puts a great deal of pressure on physicians to make the right choices and for payers to pay for new IVD technologies that may still be unproven.  As the healthcare market begins to see an aging U.S. society using more and more healthcare services, cost efficiency imperatives continue to put pressure on payers, providers and suppliers. As a result, organizations in the healthcare market have developed strict cost/performance and care guideline directives.  

This Kalorama Information report, The Wordwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition, has been updated for two decades in ten editions, keeping readers informed about developments in all areas of the IVD industry, around the world, in one volume.  The 1,600-page report provides in vitro diagnostics market size estimates and projections for the entirety of the in vitro diagnostics testing market.  The report also tracks hundreds of competitors, notes significant partnerships, distribution deals and acquisitions and defines the market share situation for the in vitro diagnostic market and competitive analysis for many segments.

Important Segment Markets in the In Vitro Diagnostic Market


Published every two years, The Worldwide Market for In Vitro Diagnostic (IVD) Tests estimates the current in vitro diagnostics market size and forecasted market size to 2021 for defined segments of the IVD market and various sub-segments, including:
  • Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
  • Clinical Chemistry and "Core Lab" Markets (including sub segment revenues for General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
  • Point-of-Care Testing (POC), (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
  • Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
  • Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
  • Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC, HPV)
  • Infectious Disease Immunoassay Testing  (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
  • Hematology
  • Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
  • Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
  • Coagulation Tests (Lab-Based, POC, Genetic Markers)
  • Sequencing and Flow Cytometry
No other report provides similar understanding of the international in vitro diagnostics market. For each of the listed in vitro diagnostics market segments, 2016 in vitro diagnostics market size, 2021 projection and compound annual growth rate is provided, as well as significant in vitro diagnostic companies in the market and IVD manufacturers' product innovations.  The market data is put into a context with real-world industry and medical practice trends. Shara Rosen (MBA, RT), has authored ten editions of this superior work intended to provide in vitro diagnostics market coverage in a world perspective.  The Worldwide Market for In Vitro Diagnostic Tests has been called "The Bible of the IVD Industry" by customers, which include top IVD firms.  Using Kalorama Information's The Worldwide Market for In vitro Diagnostic (IVD) Tests, 10th Edition, ensures that your firm will have the perspective and data of others in the in vitro diagnostics industry, as well as of those who track and invest in the IVD industry. 

Regional and Country IVD Markets 


 The in vitro diagnostics market is a global one, and The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition reflects the international scope of the in vitro diagnostics market size. In the healthcare market, IVD companies sell globally and think globally.  Trends in one part of the world affect IVD manufacturers' product decisions and company financial performance in others.  Thus, this is a global report, and the following regional and country overall IVD markets are included: 

  • US
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Netherlands
  • Turkey
  • Poland
  • Canada
  • China
  • Japan
  • Saudi Arabia
  • Brazil
  • Latin America
  • Eastern Europe
  • Emerging Markets
  • Rest of World
The Worldwide Market for In Vitro Diagnostic Tests is a testament to the Kalorama methodology. It is the result of months of painstaking work by an experienced IVD industry analyst, who has tracked hundreds of in vitro diagnostic companies for developments, trends and financial results.  This research is compiled along with the opinion, observations and insights of industry experts to produce an unparalleled vision of the in vitro diagostnics industry as it is in 2016.

In Vitro Diagnostic Companies


Kalorama Information's report, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition contains hundreds of profiles of companies operating within the in vitro diagnostics industry. Top-tier IVD companies such as Roche Diagnostics, Abbott, Siemens, Beckman Coulter, bioMerieux, Qiagen and Ortho Clinical Diagnostics are discussed at great lengthand hundreds of smaller companies are detailed. Modest in vitro diagostnics technology growth in developed countries, stronger growth in developing countries with a simultaneous shift from a preoccupation with infectious diseases to chronic conditions, is expected.  Also discussed within the report is increased privatization of healthcare services throughout the world, developed and emerging economies included and thus increased pricing pressure on all devices including in vitro diagnostics technology.   

The report concentrates over a thousand pages on detailed and tiered profiles of companies in the in vitro diagnostics market.  The experience that Kalorama Information has in the in vitro diagnostic market is evident in its tiering and segmentation of companies. 

Top Tier IVD Companies:

These are the dominant companies in the in vitro diagnostics industry.  For each company, extensive, discussion of recent financial performance is provided.  These IVD manufacturers' main products are detailed and any significant company strategies, partnerships and acquisitions are considered:   

  •  Abbott Diagnostics
  •  Alere Inc
  •  Beckman Coulter, Inc. / Danaher
  •  Becton, Dickinson and Company (BD)
  •  bioMérieux Inc.
  •  Bio-Rad Laboratories
  •  Hologic
  •  Instrumentation Laboratory (IL)
  •  Ortho Clinical Diagnostics (OCD)
  •  QIAGEN N.V
  •  Roche Diagnostics
  •  Siemens Healthineers
  •  Sysmex Corporation
  •  Thermo FisherScientific
  •  Werfen Group S.A.

Next Tier In Vitro Diagnostic Companies:

Growth-oriented companies that have significant market presence in one or several areas are profiled and their new products and strategies discussed in the report. Among these:  

  •  Affymetrix Inc. 
  •  Cepheid
  •  ERBA Diagnostics, Inc
  •  DiaSorin S.p.A
  •  Illumina
  •  Luminex Corporation
  •  Menarini Diagnostics.
  •  Mindray Medical International Limited
  •  Myriad Genetics
  •  Perkin Elmer, Inc. (PE)
  •  Quidel Corporation
  •  Randox Laboratories Ltd
  •  Royal Philips
  •  TOSOH Corporation
  •  Trinity Biotech
  •  Wako Pure Chemical Industries  

Specialist In Vitro Diagnostic Companies:

While these IVD manufacturers and companies focus on one segment of the in vitro diagnostic market, they can often be dominant in the market as well. They are important to watch because they can often develop products in new areas of  testing and move categories. 

  •  Molecular Specialists
  •  Blood Banking Specialists
  •  Point of Care Specialists
  •  Prenatal Test Service Providers
  •  Quality Control and Pretreatment Specialists
  •  CoagulationSpecialists
  •  Histology and Cytology Specialists
  •  Microbiology Specialists
  •  IT SolutionsCompanies
  •  CTC and Liquid Biopsy Specialists  

 Deep Understanding of In Vitro Diagnostic Market Trends


Published continuously for two decades, the report reflects the experience Kalorama has in watching events in IVD and the emergence and reemergence of industry, technological and clinical trends.  For instance:  

  • The revolution in bioinformatics is allowing clinical and traditional medical engineering to blend with components derived from the telecommunications, information and computer sciences industries.  This opens new niche markets for POC test devices, which will have a positive impact on diagnostic testing.
  • Getting information to care givers and patients is now not an added plus, it is a prerequisite of all lab operations.  Thus the next 3-5 years will see an intensification of the healthcare industry's emphasis on informatics, wireless communications, data networking and cost/effective healthcare delivery.   
  •  In the area of test economics, outcomes based disease management establishes guidelines and directives for patient care.  This is having a significant effect on the use of new tests, which have to prove their added value to patient care.  It also affects how many and which tests are recommended and thus reimbursed for a specific disease group. 
None of the above would be happening without significant forces in the in vitro diagnostics market driving them. Kalorama Information's The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition presents the trends, technologies, customer needs and major suppliers in the in vitro diagnostics market with an eye on how they are shaping the IVD industry, including the following industry trends:
  
  •  Top 20 In Vitro Diagnostic Companies and Niche Players 2012-2016
  •  Acquisitions in the in vitro diagnostic  Market
  •  NGS, LC-MS and Other Novel Testing
  •  Lab Market Segmentation (Hospital, Independent, POLs)
  •  Emerging Markets
  •  Digital Technology, IT and Big Data
  •  Gene Editing
  •  Wearables
  •  Europe and Austerity
  •  Status of LDTs
  •  State of Biomarker Discovery
  •  Test Services Trend
  •  Distribution Agreements
  •  Role of Sequencing
  •  Non-Blood Sampling
  •  LDT Regulatory Picture
  •  New Product Launches
  •  Near-Patient Testing
  •  DTC Testing
  •  New Testing Venues

Shifts in the Industry from 20 Years of Studying IVD


In addition to providing superior business planning tools, the following are among the many topics that The Worldwide Market for In Vitro Diagnostic Tests tackles:

  • A summary of the IVD industry from 1995 to the present. Amazingly, a lot has changed – new tests and technologies have come to market but the very same major in vitro diagnostic companies generate about 90% of product sales.
  •  Demographics: A number of world events bode well for the future of in vitro diagnostic technology: an aging worldwide population and demand for new hospitals in developing countries. Increasing numbers of people between the ages of 45 and 75 years in the industrialized world consume more healthcare services such as heart and cancer tests.  IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care. The next five to ten years or so will see moderate and gradual change in IVD product markets.   
  •  Changing Core Lab: Not 10-15 years ago, most microbiology and anatomic pathology labs were tucked away somewhere in the basement.  The major test areas similarly were separated by impenetrable walls.  Those days are long gone: imagine a centralized hospital lab where clinical chemistry, immunoassays, hematology, coagulation, urinalysis, some microbiology, some cytology tests are all performed in one room and often on instrumentation that are linked by an automated track line and all in the same room.  More importantly tests are carried out by a lab information system that consolidates test results to an electronic patient record, or EMR. 
  •  Emerging Markets: High growth countries, primarily Saudi Arabia, Brazil, China and India are experiencing in vitro diagnostics market growth of double digits. This is fueled by privatization and health insurance initiatives by governments and employers.  However this growth has a negligible effect to compensate for the lack of significant growth in major healthcare markets of Europe, Japan and the U.S. 
  •  IVD-Focused Government Initiatives: New healthcare disease screening and health insurance initiatives proposed by the new U.S.administration under the guidance of President Barack Obama further bolster the use of in vitro diagnostic technology, but continued economic difficulties has U.S. citizens forgo elective procedures because the co-payments may be somewhat unaffordable. 
  •  Automation: There is also a lack of trained lab technologists, so there is a decreasing availability of human resources needed to run the more complex new set of molecular and histological tests and immunoassays. Therefore there has been a proliferation of test and lab automation tools launched that remove precious human resources from mundane pre-analytical and sample-tracking tasks to make time for more sophisticated ones. This phenomenon was once thought to be the purview of core lab biochemistry and immunoassays but automation is becoming a common feature hematology, blood banking,microbiology, and histology. Demand for healthcare and thus in vitro diagnostic tests in all the major healthcare markets is driven by aging populations and increased incidence of conditions such as: cancer, diabetes,cardiovascular disease, arthritis and obesity. In light of the demand for these IVD tests, they have been reformulated for automated analyzers where the cost per test is traditionally low. 
  •  New Sampling: No more blood sampling: be prepared for an in vitro diagnostic market of breath tests for conditions that includes respiratory infections,gastrointestinal disorders, cancer and even chronic diseases.  Wearable patch sensors have been commercialized for glucose and vital signs monitoring; more and more applications are in development.
  • Sequencing Enters the Clinic: In the 21st century, understanding a patient’s personal genomic profile equips physicians with valuable information to better diagnose, predict, treat and prevent disease.  Personalized medicine using genomic information improves patient outcomes and reduces healthcare costs and adverse drug reactions. The NGS data analysis market includes the market by product (software and services) and by applications such as whole genome sequencing, exome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and Methyl-Seq.  As experience with sequencing intensifies, researchers are beginning to discover some of the ways in which the technology can be used.  It is generally anticipated that whole genome sequencing is most appropriate for broad research looking for linkages between gene mutations and disease development.  

Several In Vitro Diagnostic Market Trends to Significantly Impact Evolution of Disease Diagnostics:

  •  Demand for healthcare and thus diagnostic tests in all the major markets is driven by aging populations and increased incidence of conditions such as: cancer, diabetes, cardiovascular disease, arthritis and obesity.  In light of the demand for these tests, they have been reformulated for automated analyzers where the cost per test is traditionally low. 
  • IVD manufacturers' product choices have been a boon for medical care. But it also puts a great deal of pressure on physicians to make the right choices and for payers to pay for new technologies that may still be unproven.  As an aging society begins to use more healthcare services, cost efficiency imperatives continue to put pressure on payers, providers and suppliers.  As a result healthcare organizations have developed strict cost/performance and care guideline directives.  One of the ways to achieve these directives is to use medical and financial data to evaluate and prescribe the use of medical devices.   
  • What does all this mean for IVD marketers?  Data, data, and more data accompanied by the inevitable use of data to evaluate the medical usefulness and necessity of using a specific device.  Medical device usage will be based on performance data, peer review research articles, contribution to patient outcome and a cost/benefit analysis. Wide dissemination of medical information in the media and on the Internet has spawned a more informed population that is prepared to seek out new technologies.  
  • There is also a lack of trained lab technologists, so there is a decreasing availability of human resources needed to run the more complex new set of molecular and histological tests and immunoassays. Therefore there has been a proliferation of test and lab automation tools launched that remove precious human resources from mundane pre-analytical and sample-tracking tasks to make time for more sophisticated ones.  This phenomenon was once thought to be the purview of core lab biochemistry and immunoassays but automation is becoming a common feature hematology, blood banking, microbiology, and histology.   
These and many more topics are covered in Kalorama Information's report, The World Market for In Vitro Diagnostic (IVD) Tests, 10th Edition.  We publish other specific reports in molecular diagnostics, U.S. IVD, companion diagnostics and next generation sequencing and many others. Our entire library of reports are available via our Knowledge Center service at considerable savings and convenience for your company.   Order your copy today.

ONE: EXECUTIVE SUMMARY

Scope and Methodology
Size and Growth of the Market
Market Trends

TWO: INTRODUCTION

Report Design
Lab Medicine Disciplines and Applications
Market Analysis of IVD Market Segments
IVD Companies Mix and Match
Distribution Agreements
Licenses and Collaboration agreements
Test Services
Top Suppliers and Niche Players
IVDs Then and Now – A 20 Year Perspective
In the Beginning to Now
Surprises and Disappointments
Future
Point of View

THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS

Background
Population and Disease Demographics Worldwide
Emerging Markets as a Market Driver
World Segments of the IVD Market and IVD Market Evolution
Specific Country Information
The United States of America
Japan
Europe: Slow Growth - Effects of Austerity
IVD Directive Update
China
India
Brazil
Russia
Canada
Saudi Arabia
Asia Review

FOUR: TRENDS AND INNOVATION

Background
Personal Genomics – A Work in Progress
Sequencing Enters the Clinic
Digital Technology, IT, BIG Data
Gene Editing
Wearables
Breath Test Advances

FIVE: POINT-OF-CARE TESTS

Overview and Trends
Professional POC
OTC Self Testing
Colon Cancer Screening
Lipid Testing
The Major POC Test Players
Diabetes Testing – Blood Glucose Monitoring
Glucose Testing in Tight Economics
IT to Aid Diabetes Management
Diabetes Market Analysis
Blood Glucose Self-Testing
Noninvasive Testing Devices
Continuous Self Testing en Route to the Artificial Pancreas
Blood Glucose Testing by Professionals
Diabetes Testing – Glycated Hemoglobin
Genes and Other Markers of Diabetes

SIX: THE CORE LAB

Core Lab Overview and Trends
Connectivity
Overview of Chemistry Tests
Lab Automation
Market Analysis
Rapid Response Systems
Critical Care Analysis
User Apps
Urinalysis
The Commercial Outlook for Chemistry Tests

SEVEN: IMMUNOASSAYS

Overview and Trends
Immunoassay Technology Continues to Evolve
Mass Spectrometry
Immunoassays in the Core Lab
Radioimmunoassays
Market Analysis
Leading Suppliers and Growth Potential
Mature Assay Segment
Thyroid Function
Therapeutic Drug Monitoring
Anemia
Toxicology/DAU
Allergy
Maturing Immunoassays
Proteins
Growth Immunoassays
Vitamin D
Tumor Markers
Cardiac Markers
Autoimmune
Rheumatoid Arthritis
Gastrointestinal Disorders
Transplant Management
Women’s Health
Alzheimer’s Disease
Miscellaneous
Point-of-Care OTC and Professional Use
Pregnancy Testing
Cardiovascular Diagnostics
Drugs of Abuse/Therapeutic Drug Monitoring
The Commercial Outlook for Immunoassays

EIGHT: MOLECULAR ASSAYS

Overview
Sample Preparation and Quality Control
Advanced Molecular Tests and Technologies
Exosome Sequencing
Liquid Biopsy
Metabolomic Profiling
Information Technology for Test Value
Forensic Studies – An Emerging Opportunity
Test Platforms
Major Players
Market Analysis
Oncology
Inherited Diseases
Prenatal and Newborn Testing
Tissue Typing
The Commercial Outlook for Molecular Tests

NINE: HEMATOLOGY

Overview of Hematology and Trends
Digital Image Analysis
Digital Evolution
Decentralized Hematology Testing
Hemoglobin/Hematocrit at the POC
Market Analysis: Leading Suppliers
The Commercial Outlook for Hematology Tests

TEN: COAGULATION

Overview and Trends of Coagulation and Immunohematology Tests
Special Topics
Direct Oral Anticoagulants (DOACs)
D-dimer
Market Analysis
Lab-based Testing
Genetic Markers of Hypercoagulopathies
Decentralized Coagulation Testing – Professional Use
Decentralized Coagulation Testing – OTC
Platelet Testing
Leading Suppliers
The Commercial Market for Coagulation Tests

ELEVEN: MICROBIOLOGY AND VIROLOGY

Overview
Special Topics
Some Disease Facts
Pregnancy Infections – Beyond Zika
Emerging Disease Threats
Antimicrobial Drug Resistance
Mass Spectrometry Not a Pipedream
Infection Screening Serology
Microbiome – Bacteria in Disease Processes
Market Analysis
Supplies
Chromogenic Media
Microbial Identification and Antimicrobial Sensitivity Tests
Automated Microbiology
Blood Culture
Rapid Tests
Immunoassays – Lab-based
Immunoassays – Rapid
Molecular Tests
The Commercial Outlook for Microbiology / Virology Tests

TWELVE: BLOOD BANKING SERVICES

Overview and Trends
are all these transfusions good medicine
Artificial blood
Pathogen Alerts
Platelet Safety
Market Analysis
Blood Grouping and Typing
Immunoassays
Nucleic Acid Testing (NAT)
The Commercial Outlook for Blood Banking

THIRTEEN: HISTOLOGY AND CYTOLOGY

Overview
Special Topics
Histology Automation
Advanced Analysis Solutions
HPV Goes Core Lab
Market Analysis
Histology/Cytology
Immunohistochemistry and In Situ Hybridization
Pharmacodiagnostic Histology
Digital Imaging and Computational Pathology
Circulating Tumor Cells
Flow Cytometry
The Commercial Outlook for Histology and Cytology Tests

FOURTEEN: COMPANY PROFILES: THE TOP TIER

Abbott Diagnostics
   Recent Revenue History:
   2014/2015 Business Highlights
   Core Lab
   Immunoassays
   Hematology
   Coagulation
   Blood Bank
   Point of Care
   Diabetes
   Molecular
   IntelligentMDx Alliance
   Iridica
   Histology
Alere Inc
   Recent Revenue History:
   Alere in Africa
   Product News
   Microbiology
   Molecular
Arkray
   Recent Revenue History:
   Urinalysis
   Diabetes
   Molecular
Beckman Coulter, Inc. / Danaher
   Recent Revenue History:
   Core Lab
   Hematology
   Immunoassays
Iris International
   Microbiology
   Molecular
   Sequencing
   Genomics
   Information Technology
   Flow Cytometry
Becton, Dickinson and Company (BD)
   Recent Revenue History:
   Traditional Microbiology
   Blood Culture
   Mass Spectrometry
   Veritor System - Immunoassays
   Histology
   HPV
   Molecular
   The BD MAX Enterprise
   Sequencing
   Flow Cytometry
bioMérieux Inc
    Recent Revenue History:
    Traditional Microbiology
    Blood Culture
    Immunoassays
    Rapid Tests
    Oncology
    Mass Spectrometry
    Molecular Strategy
    Sequencing Service
    Expansion
Bio-Rad Laboratories, Inc
    Recent Revenue History
    Controls
    Diabetes
    Blood Bank
    Immunoassays
    Flow Cytometry
    Digital PCR
Danaher Corporation
    Recent Revenue History
Hologic, Inc
    Recent Revenue History:
    The Gen-Probe/PANTHER Business
    Blood Bank
    Quest Contract
Instrumentation Laboratory (IL)
    Recent Revenue History: ($ millions)
    Coagulation
    Direct Oral Anticoagulant Testing (DOAC)
    Coagulation Automation
    Critical Care
Ortho Clinical Diagnostics (OCD)
    Recent Revenue History:
    Blood Bank
QIAGEN N.V
    Recent Revenue History
    Tuberculosis
    Infectious Disease Testing
    Transplant Medicine and HAIs
    Personalized Healthcare
    Companion Diagnostics
    Liquid Biopsy/CTC
    Instrumentation Base
    Rotor-Gene Q – Clinical Diagnostics
    Sequencing
    Exosomes
    Information Technology
    Collaborations
    Forensics
Radiometer A/S
    Recent Revenue History:
    Immunoassays
    Hemocue AB
Roche Diagnostics
    Recent Revenue History
    New Enterprises
    Global Access Program for HIV
    Core Lab
    Hematology
    Immunoassays
    Transplant Medicine
    Diabetes
    Point of Care
    Core Molecular Tests
    Virology
    STDs
    A POC Enterprise – Liat
    Prenatal and cfDNA
    HPV
    Blood Bank
    Liquid Biopsy
    Personalized Medicine
    Sequencing – Putting the Pieces Together
Siemens Healthcare Diagnostics
    Recent Revenue History:
    Core Lab
    Immunoassays
    Urinalysis
    Critical Care
    POC Connectivity
    Hematology
    Histology
    Coagulation
    Molecular
    Companion Diagnostics
    China
Sysmex Corporation
    Recent Revenue History:
    Hematology
    Coagulation
    Core Lab
    Inostics GmbH
    Flow Cytometry 
    Thermo Fisher Scientific Inc
    Recent Revenue History:
    Sequencing
    Microbiology
    Microbiology IT
    Transplant
    Quality Control
    Mass Spectrometry
    Point of Care
    Molecular
    Oncology
    Forensic
Werfen Group S.A

FIFTEEN: Company Profiles: The Second Tier

Affymetrix Inc
     Recent Revenue History
     Axiom Genotyping Applications
     Agilent Technologies
     Recent Revenue History:
     Agilent in Genomics
     PCR
     Sequencing
     Arrays
Cepheid
     Recent Revenue History:
     Hospital Acquired Infections (HAI)
     TB
     Infectious Diseases
     Virology
     Oncology
Eiken Chemical Co., Ltd
     Recent Revenue History:
ERBA Mannheim
ERBA Diagnostics, Inc
     Recent Revenue History:
     Product Expansion
DiaSorin S.p.A
     Recent Revenue History:
     Immunoassays
     Molecular
Fujirebio Diagnostics, Inc
     Recent Revenue History:
     Molecular
Illumina
     Recent Revenue History:
     Understand Your Genome Symposium
     Sequencing
     Sequencing Kits
     Sample Prep
     IVD Business
     Oncology
     HLA Typing
     Information Technology  
     CRISPR
     Forensics
     CLIA Lab Service
     Sample to Insight
     Making a Market
     Expansion in China
LabCorp, Laboratory Corporation of America
     Recent Revenue History:
     Infectious Diseases
     Prenatal
     Sequencing
     Oncology
     Information Technology
     Forensic
     Expanding Food Testing
Luminex Corporation
     Recent Revenue History: $ million
     Business Expansion
     MAGPIX Multiplexing
     Next Generation NxTag
Menarini Diagnostics
     Recent Revenue History:
Mindray Medical International Limited
      Recent Revenue History:
      Core Lab
     Hematology
     Coagulation
Myriad Genetics
      Recent Revenue History: (millions)
      Molecular Product News
      Beyond Cancer
      IP Update
PerkinElmer, Inc. (PE)
      Recent Revenue History: ($ million, estimated)
      Newborn Testing
      Prenatal Testing
      Histology
      Information Technology
      India
      China
Quest Diagnostics
      Recent Revenue History:
      Oncology
      Infectious Diseases
      Prenatal and Women’s Health
      Market Expansion
      Insurance and Wellness Business
Quest Partners for Market Accessibility
      Information Technology
Quidel Corporation
      Recent Revenue History:
      Point of Care
      Immunoassays
      Molecular
      Lyra Product Line
      Solana Molecular System
      AmpliVue Product Line
      Savanna (formerly Wildcat)
Randox Laboratories Ltd
      Recent Revenue History:
      Controls
      Immunoassays
      Molecular
      Prenatal
      POC
Royal Philips
      Histology
      Point of Care
TOSOH Corporation
      Recent Revenue History 
      Immunoassays
      Transasia Bio-Medicals Ltd
Trinity Biotech plc
      Recent Revenue History
Wako Pure Chemical Industries, Ltd
      Recent Revenue History

SIXTEEN: COMPANY PROFILES: BLOOD BANK SPECIALISTS

BloodSource
Cerus Corporation
Grifols
Clinical Analysis
Blood Transfusion Business
International Programs
Molecular
Haemokinesis Pty Ltd
Immucor, Inc
Transfusion Medicine
Transplant Diagnostics
IMMUCOR DX Laboratory Service
Micro Typing Concepts (MTC)
Quotient Limited
Traditional Blood Grouping
MosaiQ Platform

SEVENTEEN: COMPANY PROFILES: COAGULATION SPECIALISTS

Diagnostica Stago, S.A.S
      Recent Revenue History
     Instrumentation
     Test Kits
Microvisk Technologies

EIGHTEEN: COMPANY PROFILES: CORE LAB AND OTHER COMPANIES

AB SCIEX Pte Ltd
Bruker BioSciences Corporation
     Recent Revenue History
     Microbiology
     Tissue Analysis
EKF Diagnostics Holdings Plc
     Recent Revenue History
     Lab-based Assays
     Molecular
EliTech Group S.A.S
MedTest DX
Microsaic Systems plc
Nova Biomedical
Diabetes
Scienion AG
Sekisui Diagnostics
Shimadzu Scientific Instruments
Tecan Group
     Recent Revenue History

NINETEEN: COMPANY PROFILES: CTC & LIQUID BIOPSY TEST PROVIDERS

Angle plc
ApoCell, Inc
Biocept, Inc
     Recent Revenue History
     Menu Expansion
     Reimbursement
Biodesix, Inc
Celsee Diagnostics (formerly DeNovo Sciences, Inc.)
Circulogene Theranostics
Clearbridge BioMedics
Cynvenio Biosystems, Inc
Epic Sciences Inc
Collaborations
Exosome Diagnostics, Inc
Fluxion Biosciences, Inc
Genyo – Centre for Genomics
Janssen Diagnostics, LLC (formerly Veridex, LLC)
     Recent Revenue History
Menarini-Silicon Biosystems
Qiagen Hanover
     Recent Revenue History
ScreenCell
WaveSense LLC

TWENTY: COMPANY PROFILES: DIABETES SPECIALISTS

Animas Corporation
     Recent Revenue History
Ascensia Diabetes Care (formerly Bayer Diabetes Care)
Recent Revenue History
Bigfoot Biomedical
Cellnovo Group
     Recent Revenue History
Debiotech SA
DexCom, Inc
     Recent Revenue History
Dexcom Product Overview
     Collaborations
Diasend AB
     Recent Revenue History
Gentag, Inc
Gentag’s Patent Position
Glucosense Diagnostics Ltd
Glysure Limited
Glytec Inc
iHealth Lab Inc
Insulet Corporation
     Recent Revenue History
Neighborhood Diabetes Inc
Integrity Applications Inc
LabStyle Innovations Corp
     Recent Revenue History
Lifescan Inc
     Recent Revenue History
     IP Issues
     Medtronic Inc
     Recent Revenue History
Nemaura Medical, Inc
Nightscout
Nipro Diagnostics, Inc
     Recent Revenue History:
Sanofi Diabetes
     Recent Revenue History
Tandem Diabetes Care, Inc
     Recent Revenue History
TypeZero Technologies
Verily (formerly Google Life Sciences)

TWENTY-ONE: COMPANY PROFILES: HEMATOLOGY (CELL ANALYSIS) SPECIALISTS

CellaVision AB
Recent Revenue History
Horiba Medical
Recent Revenue History
Chemistry
Medica Corporation
Oncascan Limited
West Medica
Zyomyx Inc

TWENTY-TWO: COMPANY PROFILES: HISTOPATHOLOGY SPECIALISTS

Advanced Cell Diagnostics (ACD)
Amoy Diagnostics Co. Ltd
Applied Spectral Imaging Inc. (ASI)
BioGenex Laboratories Inc
BioView Ltd
Recent Revenue History
Circulomics Inc
Dako A/S
Recent Revenue History
Special Stains
Immunohistochemistry (ICH)
Companion Diagnostics
Flow Cytometry
Automation
Alliances
Definiens
EMD Millipore
HTG Molecular Diagnostics
Recent Revenue History
Kapa Biosystems Inc
Leica Biosystems
Collaborations
Omnyx LLC
Ventana Medical Systems Inc
Recent Revenue History
Digital Pathology
Virtuoso Software Update
Product News
Automation
Partnerships
Visiopharm

TWENTY-THREE: COMPANY PROFILES: IMMUNOASSAY SPECIALISTS

BG Medicine, Inc
Recent Revenue History
Binding Site Group Ltd. (The)
Recent Revenue History
Biohit Oyj
Recent Revenue History
Market Expansion
Biomerica Inc
Recent Revenue History
Bio-Techne Corporation
Recent Revenue History
Corgenix Medical Corporation
Critical Diagnostics
Diaxonhit
Recent Revenue History
Euroimmun AG
Recent Revenue History
Hob Biotech
Immunodiagnostic Systems (IDS)
Recent Revenue History
INOVA Diagnostics, Inc
Integrated Diagnostics (Indi)
One Lambda
Recent Revenue History
Orgentec Diagnostika
Recent Revenue History
Protagen Diagnostics
Quanterix Corporation
Response Biomedical Corp
Recent Revenue History
Singulex, Inc
Theradiag
Recent Revenue History
VolitionRx Limited

TWENTY-FOUR: COMPANY PROFILES: INFORMATION TECHNOLOGY SPECIALISTS

Advaita Bioinformatics
Apple Inc
Cartagenia
Cerner Corp
CLC bio
Cypher Genomics Inc
Dell Healthcare and Life Sciences
Desktop Genetics, Ltd
DNAnexus
Edico Genome
Euformatics Oy
GENALICE
GenomOncology
Google Genomics (Alphabet)
IBM Healthcare
Intel Corporation
Knome Inc
Collaborations
N-of-One
PierianDx
Rennova Health, Inc
Sophia Genetics
Sunquest Information Systems
Tute Genomics
WuXi NextCODE Genomics

TWENTY-FIVE: COMPANY PROFILES: MICROBIOLOGY SPECIALISTS

Accelerate Diagnostics, Inc
Advanced Biological Laboratories, S.A. (ABL)
AdvanDx, Inc
altona Diagnostics
ArcDia International Oy Ltd
BioFire Diagnostics, Inc
Recent Revenue History
Copan Diagnostics Inc
Lab Automation
Partnerships
Swabs
Curetis AG
Fast-Track Diagnostics
Focus Diagnostics, Inc
Genetic Analysis AS
GeneWeave Biosciences, Inc
About Smarticle Technology
Great Basin Scientific, Inc
Greiner Bio-One International GmbH
Preanalytical Products
Hain Lifescience GmbH
Meridian Bioscience, Inc
Recent Revenue History
Immunoassays
illumigene
Meridian Life Science
Sample Collection
Mobidiag Ltd
Nanosphere, Inc
Recent Revenue History
Market Expansion
PositiveID Corporation
Recent Revenue History
Seegene, Inc
Recent Revenue History
Instrumentation
Collaborations
Specific Technologies
Synbiosis Ltd
T2 Biosystems
Recent Revenue History
ViroCyt, LLC

TWENTY-SIX: COMPANY PROFILES: MOLECULAR TEST SPECIALISTS

Agena Bioscience
Market Expansion
Asuragen Inc
Controls
Sample Collection
Sequencing
AutoGenomics Inc
BGI (formerly Beijing Genome Institute)
Prenatal Testing
Liquid Biopsy
With Complete Genomics
BGI Projects
Biocartis Group
Recent Revenue History
Connectivity
DMAT Instrumentation - MyCartis
Idylla News
Infectious Diseases
Building the Future
Collaborations
Enzo Biochem Inc
Recent Revenue History
IP Situation
Epigenomics
Exosome Diagnostics, Inc
Fluidigm Corporation
Recent Revenue History
GenMark Diagnostics
Recent Revenue History
Genome Diagnostics BV (GenDx)
Life Technologies Corporation
Instrumentation and Applications
Liquid Biopsy
Sequencing
Life Technologies an IVD company
Emerging Pathogens
Bacterial Typing
Forensic
Nanostring Technologies, Inc
Recent Revenue History
Immunohistochemistry
Alliances
LDTs
Oxford Nanopore Technologies Ltd
Pacific Biosciences of California, Inc. (PacBio)
Recent Revenue History
QuanDx Inc
RainDance Technologies, Inc
Recent Revenue History
Market Expansion
Rubicon Genomics, Inc
Transgenomic, Inc
Alliances
Lab Services
Diagnostic Tools Division
TrovaGene, Inc
Vela Diagnostics
WaferGen Bio-systems, Inc
Recent Revenue History

TWENTY-SEVEN: COMPANY PROFILES: POINT OF CARE TEST SPECIALISTS


Abaxis, Inc
Recent Revenue History
Abingdon Health Ltd
Atlas Genetics Ltd
Biomeme, Inc
Chembio Diagnostic Systems, Inc
Recent Revenue History
DNA Electronics Ltd (DNAe)
Enigma Diagnostics Limited
Entopsis
Epistem Holdings plc
FABPulous B.V
Fio Corporation
Hema Diagnostic Systems (HDS)
Imec
InSilixa Inc
MedMira Inc
OraSure Technologies, Inc
Recent Revenue History
The Genotek Business
PTS Diagnostics
QloudLab SA
QuantuMDx Group Limited
Rheonix, Inc
Samsung Healthcare
Scanadu, Inc
Theranos, Inc
Veredus Laboratories Pte Ltd
Xagenic

TWENTY-EIGHT: COMPANY PROFILES: PRENATAL TEST SERVICE PROVIDERS

Ariosa Diagnostics, Inc
Berry Genomics Co. Ltd
Combimatrix Corp
Recent Revenue History
Good Start Genetics, Inc
Illumina
IP Issues
Cytogenetics
Inex Innovations Exchange
LifeCodexx AG
MAP Diagnostics Ltd
Multiplicom N.V
Natera
Recent Revenue History
Oncology – Planning for the Future
Premaitha Health plc
Sequenom Inc
Recent Revenue History
Market Expansion
Product Expansion
IP Issues
Oncology
Coagulation

TWENTY-NINE: COMPANY PROFILES: QUALITY CONTROL & SAMPLE PRETREATMENT SPECIALISTS

Horizon Discovery Group plc
Recent Revenue History
Collaborations
MO BIO Laboratories, Inc
Oasis Diagnostics Corporation
PreAnalytiX GmbH
SeraCare Life Sciences, Inc
Streck Inc
THIRTY: COMPANY PROFILES: TEST SERVICE PROVIDERS
23andMe
The Move to Building a Research Company
Therapeutics Group
Ancestry
Outside the U.S
Agendia BV
Recent Revenue History
Ambry Genetics
Epilepsy
Oncology
Cardiac
Prenatal
Information Technology
ARUP Laboratories
Assurex Health
BioCollective (The)
Bio-Reference Laboratories, Inc. (BRLI)
bioTheranostics
BluePrint Genetics Oy
Boston Heart Diagnostics
CareDx, Inc. (Formerly XDx, Inc.)
Recent Revenue History
Sequencing
Cleveland HeartLab Inc
Counsyl
Eurofins Genomics
Exact Sciences Corp
Recent Revenue History
Foundation Medicine Inc
Recent Revenue History
Collaborations
Genomic Health, Inc
Recent Revenue History
Market Uptake
Liquid Biopsy
Service Spin-off
Genomic Vision
Recent Revenue History
Helomics Corporation (formerly Precision Therapeutics, Inc)
Mayo Medical Laboratories
Information Technology
MDxHealth SA
Recent Revenue History
OPKO Diagnostics
Pathway Genomics Corporation
Rosetta Genomics Ltd
Recent Revenue History
Expansion
Sonic Healthcare
Recent Revenue History
Veracyte, Inc
Recent Revenue History
Vermillion Inc
Recent Revenue History



-------------------------------------List of Exhibits----------------------------------------




ONE: EXECUTIVE SUMMARY
Table 1-1
Exchange Rate Fluctuations, 2012–2016
Table 1-2
Worldwide In Vitro Diagnostic Reagent Sales by Market Segment, 2016-2021

TWO: INTRODUCTION
Table 2-1
Worldwide In Vitro Diagnostic Sales by Product Market, 2016-2021
Table 2-2
Selected Diagnostics Industry Acquisitions, 2014, 2015 and H2 2016
Table 2-3
Selected Diagnostics Industry Distribution Agreements, 2014, 2015, H2 2016
Table 2-4
Selected IVD collaboration/Licensing Agreements, 2014, 2015, H2 2016
Table 2-5
Selected Test Services, Sales 2012-2016
Table 2-6
Lab Market Segmentation, Worldwide, 2016
Table 2-7
Revenues for a Selection of U.S.-based Reference Labs, 2012-2016
Table 2-8
Selected Company sponsored Labs Established in 2014 and 2015
Table 2-9
Revenues of Selected Top IVD Companies, 2012-2016
Table 2-10
Revenues of Selected Niche Players, 2012-2016
Table 2-11 IVD Test Segment Sales 1995-2015

THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS
Table 3-1
World Population Distribution, 2016
Table 3-2
Selected Disease Statistics, Worldwide
Table 3-3
Elderly Support Ratio in Selected Countries (2050)
Table 3-4
Available Market Data, 2016
Table 3-5
Worldwide In Vitro Diagnostic Reagent Sales by Country/Region, 2016-2021
Figure 3-1: EU IVD Revenue Stream 2007-2016
Table 3-6
European Union (EU14) IVD Sales by Country 2014
Table 3-7
Per Capita IVD Expenditure

FOUR: TRENDS AND INNOVATION
Table 4-1
Selected Sequencing Platforms
Table 4-2
Selected IVD industry IT Investments
Table 4-3
Selected Gene Editing Research Kits
Table 4-4
Selected Wearable Devices
Table 4-5
Selected Disease Markers in Exhaled Breath
Table 4-6
Selected Breath Test Innovations

FIVE: POINT-OF-CARE TESTS
Table 5-1
Professional POC Test Sales by Category, Worldwide, 2016-2021
Table 5-2
Hospital POC Test Usage, U.S
Table 5-3
Selected Profession POC Test Innovations
Table 5-4
POC Self Test Sales by Category, Worldwide, 2016-2021
Table 5-5
POC Test Revenues of Selected IVD Companies, 2013-2015
Table 5-6
Selected Apps and Glucose Management IT
Table 5-7
Diabetes Sales by Test Category, Worldwide, 2016-2021
Table 5-8
World Glucose Monitoring Sales, Major Companies, 2012-2016
Table 5-9
Selected Glucose Self-Test Meter Innovations
Table 5-10
Selected Noninvasive Glucose Monitoring Devices
Table 5-11
Selected Continuous BGM Sales, 2013 – 2016
Table 5-12
Selected Continuous Blood Glucose System Developments
Table 5-13
Selected Innovations in Hospital-based Glucose Monitoring
Table 5-14
Selected POC HbA1c Devices
Table 5-15
Selected POC Diabetes Monitoring Tests

SIX: THE CORE LAB
Table 6-1
Workstation Sales, 2016-2021 (General Chemistries, Immunos on workstations)
Table 6-2
Core Lab Sales of the Top Five Manufacturers, 2012-2016
Table 6-3
Selected New Analytes for the Core Lab, 2014-2015
Table 6-4
Selected Lab Automation Innovations
Table 6-5
Worldwide Clinical Chemistry Sales by Test Category, 2016-2021
Table 6-6
Major Clinical Chemistry Companies
Table 6-7
Selected Clinical Chemistry Innovations
Table 6-8
Major Whole Blood Chemistry Analyzers
Table 6-9
Selected Apps, Critical Care and Urinalysis IT Innovations, 2016
Table 6-10
Selected Urinalysis Innovations, 2016

SEVEN: IMMUNOASSAYS
Table 7-1
Selected New Immunoassay Technologies, 2016
Table 7-2
Selected Innovation in Mass Spectrometry for Routine Analyses
Table 7-3
Selected Immunoassay Innovations on Core Lab Instruments
Table 7-4
Worldwide Lab-based Immunoassay Sales by Analyte Type, 2016-2021
Table 7-5
Selected Immunoassay Quality Control Products
Table 7-6
Revenue History of Leading Immunoassay Vendors, 2012-2016
Table 7-7
Selected New Vitamin D Immunoassays, 2014-2016
Table 7-8
Selected Tumor Marker Innovations, 2014-2016
Table 7-9
Selected Cardiac Marker Innovations
Table 7-10
Selected Autoimmune Test Innovations
Table 7-11
Selected Arthritis Immunoassay Innovations
Table 7-12
Selected Inflammatory Bowel Disease Test Innovations
Table 7-13
Selected Immunoassays for Transplant Medicine
Table 7-14
Selected Women’s Health Innovations
Table 7-15
Selected Innovations for Alzheimer’s Disease Immunoassays
Table 7-16: Selected Immunoassay Innovations
Table 7-17
POC Immunoassay Test Sales by Test Category, 2016-2021
Table 7-18
Selected Self-Test Immunoassay Innovations
Table 7-19
Selected Professional POC Test Innovations, 2016
Table 7-20
Selected POC Immunoassay Test Platforms

EIGHT: MOLECULAR ASSAYS 310
Table 8-1
Common Next Generation Molecular Test Traits
Table 8-2
Selected Molecular Test Sample Preparation and QC Innovations
Table 8-3
Selected Exosome Test Innovations
Table 8-4
Selected Liquid Biopsy Innovations
Table 8-5
Selected IT Innovations in Molecular Diagnostics
Table 8-6
Selected Innovations in Forensic DNA Testing
Table 8-7
Key Molecular Technologies and Major Players
Table 8-8
Selected Molecular Test Platform Innovations
Table 8-9
Molecular Test Revenues of Selected IVD Vendors, 2012-2016
Table 8-10
Worldwide Molecular Test Sales by Type, 2016-2021
Table 8-11
Selected Molecular Tumor Marker Test Innovations
Table 8-12
Most Frequently Requested Genetic Tests
Table 8-13
Selected Genomic Tests for Inherited Diseases
Table 8-14
Revenue Stream of Selected NIPT Service Companies, 2012-2015
Table 8-15
Prenatal Services Provided
Table 8-16
Selected Molecular Tests for Prenatal Analysis
Table 8-17
Selected HLA Typing Test Innovations

NINE: HEMATOLOGY
Table 9-1
CellaVision Placement Data by Hematology Vendor
Table 9-2
Selected Hematology Image Analysis Innovations, 2014-2015
Table 9-3
Selected POC Hematology Innovations
Table 9-4
Revenue History of the Major Hematology Vendors, 2012-2016
Table 9-5
Selected Hematology Innovations, 2016

TEN: COAGULATION
Table 10-1
Worldwide Coagulation Sales by Segment, 2016-2021
Table 10-2
Selected Lab-based Coagulation Innovations, 2016
Table 10-3
Selected Molecular Coagulation Test Innovations
Table 10-4
Selected POC Coagulation Test Innovations
Table 10-5
Top Coagulation Company Revenues, Lab & POC, 2012 – 2016
Table 10-6
Major Anticoagulants Uses and Tests

ELEVEN: MICROBIOLOGY AND VIROLOGY
Table 11-1
Global Deaths from Communicable Diseases, 2010
Table 11-2
Selected Tests for Emerging Pathogens
Table 11-3
Selected Tests for Antibiotic Resistance
Table 11-4
Selected Microbiology Mass Spec Innovations
Table 11-5
Selected Microbiome-based Tests
Table 11-6
Worldwide Microbiology/Virology Sales by Type, 2016-2021
Table 11-7
Selected Innovations in Microbiology Pre-Analytical Products
Table 11-8
Selected Innovations in Bacterial Identification
Table 11-9
Selected Antibiotic Sensitivity Test Innovations
Table 11-10
Revenue of Selected Microbiology Companies, 2013, 2016
Table 11-11
Selected Advanced Techniques for Positive Blood Cultures
Table 11-12
Lab-based Infectious Disease Immunoassays, by Test, 2016
Table 11-13
Selected Infectious Disease Immunoassay Innovations
Table 11-14
Selected Professional Use POC Tests for Infectious Diseases
Table 11- 15: Selected Molecular Test Platform Innovations, 2014-2016
Table 11-16
Selected Microbiology Sequencing Innovations
Table 11-17
Molecular Test Sales, Infectious Diseases, 2016
Table 11-18
Selected Molecular HAI Test Innovations
Table 11-19
Selected Molecular Tests for STDs
Table 11-20
Selected Molecular Respiratory Disease Innovations
Table 11-21
Selected Molecular HIV Test Innovations
Table 11-22
Selected Infectious Disease Molecular Test Innovations
Table 11-23
Selected Molecular POC Device Innovations

TWELVE: BLOOD BANKING SERVICES
Table 12-1
Blood Donation, Key Facts
Table 12-2
Distribution of Blood Units Collected
Table 12-3
Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries (Syphilis, HCV, HBV, HIV)
Table 12-4
Blood Component Usage (Liver Transplant, Adult Open Heart Surgery, Automobile Accident, Leukemia, Sickle Cell Disease, Cancer Chemotherapy)
Table 12-5
Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)
Table 12-6
Worldwide Blood Bank Sales, 2016-2021
Table 12-7
Selected Blood Grouping Innovations
Table 12-8
Selected New Blood Screen NAT Tests and Systems

THIRTEEN: HISTOLOGY AND CYTOLOGY
Table 13-1
Selected Histology Lab Automation
Table 13-2
Histology Information Technology Tools
Table 13-3
Selected Advanced Histology Techniques
Table 13-4
Selected HPV Test Innovations
Table 13-5
Worldwide Histology/Cytology Sales by Type, 2016-2021
Table 13-6
Revenues of the Major Histology Companies, 2012-2016
Table 13-7
Selected Vendors Of Traditional Histology Stains
Table 13-8
Selected In Situ Hybridization-based Tests
Table 13-9
Selected IHC Test Innovations
Table 13-10
Major Pharmacodiagnostic Markers
Table 13-11
Selected Pharmacodiagnostic Histology Tests
Table 13-12
Selected Digital Imaging Innovations
Table 13-13
Selected Innovations in CTC Technology

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.